Immunotherapy of hepatocellular carcinoma with infection of hepatitis B or C virus

Abstract

Hepatocellular carcinoma (HCC) has one of highest mortalities globally amongst cancers, but has limited therapeutic options once in the advanced stage. Hepatitis B or C virus infection are the most common drivers for HCC carcinogenesis, triggering chronic liver inflammation and adding to the complexity of the immune microecosystem of HCC. The emergence of immunotherapy has afforded a new avenue of therapeutic options for patients with advanced HCC with a history of hepatitis B or C virus infection. This article reviews the change of immunity elicited by hepatitis B or C virus infection, the immune feature of HCC, and the clinical evidence for immunotherapy in advanced HCC and discusses future directions in this field.

Keywords

Hepatocellular carcinoma / hepatitis B virus / hepatitis C virus / immunotherapy

References

[1] Mathers CD.Projections of global mortality and burden of disease from 2002 to 2030..PLoS Med2006;3:e442 PMCID:PMC1664601

[2] Arnold M,Neale RE,Giovannucci EL.Global burden of 5 major types of gastrointestinal cancer..Gastroenterology2020;159:335-49.e15

[3] Bray F,Soerjomataram I,Torre LA.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries..CA Cancer J Clin2018;68:394-424

[4] Lok AS,Morgan TR,Sterling RK.Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease..Gastroenterology2009;136:138-48 PMCID:PMC3749922

[5] Jemal A,Center MM,Ward E.Global cancer statistics..CA Cancer J Clin2011;61:69-90

[6] Chen CJ,Su J,You SL.Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level..JAMA2006;295:65-73

[7] Lee MH,Lu SN,Yeh SH.Hepatitis C virus seromarkers and subsequent risk of hepatocellular carcinoma: long-term predictors from a community-based cohort study..J Clin Oncol2010;28:4587-93

[8] Chang MH,Chen CJ,Lee CM.Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study..J Natl Cancer Inst2009;101:1348-55

[9] Kanwal F,Asch SM,Cao Y.Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents..Gastroenterology2017;153:996-1005.e1

[10] Fujiwara N,Goossens N.Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine..J Hepatol2018;68:526-49 PMCID:PMC5818315

[11] Llovet JM,Mazzaferro V,Gane E.Sorafenib in advanced hepatocellular carcinoma..N Engl J Med2008;359:378-90

[12] Kudo M,Qin S,Ikeda K.Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial..Lancet2018;391:1163-73

[13] Bruix J,Merle P,Huang Y.Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial..Lancet2017;389:56-66

[14] Abou-Alfa GK,Cheng AL,Rimassa L.Cabozantinib in patients with advanced and progressing hepatocellular carcinoma..N Engl J Med2018;379:54-63 PMCID:PMC7523244

[15] Zhu AX,Yen C,Galle PR.Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial..Lancet Oncol2019;20:282-96

[16] Postow MA,Wolchok JD.Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma..Cancer J2012;18:153-9 PMCID:PMC3751414

[17] Belloni L,De Nicola F,Raffa G.Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function..Proc Natl Acad Sci U S A2009;106:19975-9 PMCID:PMC2775998

[18] Dunn C,Khanna P,Jones M.Temporal analysis of early immune responses in patients with acute hepatitis B virus infection..Gastroenterology2009;137:1289-300

[19] Sato S,Kameyama T,Ishida Y.The RNA sensor RIG-I dually functions as an innate sensor and direct antiviral factor for hepatitis B virus..Immunity2015;42:123-32

[20] Shlomai A,Ramanan V,de Jong YP.Modeling host interactions with hepatitis B virus using primary and induced pluripotent stem cell-derived hepatocellular systems..Proc Natl Acad Sci U S A2014;111:12193-8 PMCID:PMC4143014

[21] Stacey AR,Qin L,Taylor E.Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections..J Virol2009;83:3719-33 PMCID:PMC2663284

[22] Wieland S,Purcell RH.Genomic analysis of the host response to hepatitis B virus infection..Proc Natl Acad Sci U S A2004;101:6669-74 PMCID:PMC404103

[23] Boltjes A,Biesta PJ,Kwekkeboom J.Kupffer cells interact with hepatitis B surface antigen in vivo and in vitro, leading to proinflammatory cytokine production and natural killer cell function..J Infect Dis2015;211:1268-78

[24] Wu J,Jiang M,Trippler M.Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells..Hepatology2009;49:1132-40

[25] Tu Z,Pierce RH,Crispe IN.TLR-dependent cross talk between human Kupffer cells and NK cells..J Exp Med2008;205:233-44 PMCID:PMC2234385

[26] Fisicaro P,Boni C,Mori C.Early kinetics of innate and adaptive immune responses during hepatitis B virus infection..Gut2009;58:974-82

[27] Lunemann S,Hengst J,Grabowski J.Compromised function of natural killer cells in acute and chronic viral hepatitis..J Infect Dis2014;209:1362-73

[28] Oliviero B,Paudice E,Zaramella M.Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections..Gastroenterology2009;137:1151-601160.e1-7

[29] Asabe S,Chattopadhyay PK,Engle RE.The size of the viral inoculum contributes to the outcome of hepatitis B virus infection..J Virol2009;83:9652-62 PMCID:PMC2748002

[30] Rehermann B.Immunology of hepatitis B virus and hepatitis C virus infection..Nat Rev Immunol2005;5:215-29

[31] Rehermann B,Pasquinelli C.The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response..Nat Med1996;2:1104-8

[32] Sun C,Xiao WH,Tian ZG.Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy..Acta Pharmacol Sin2015;36:1191-9 PMCID:PMC4648180

[33] Hoechst B,Ormandy L,Zhao F.Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor..Hepatology2009;50:799-807 PMCID:PMC6357774

[34] Peppa D,Javaid A,Schurich A.Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection..PLoS Pathog2010;6:e1001227 PMCID:PMC3003000

[35] Kong X,Chen Y,Tian Z.γδT cells drive myeloid-derived suppressor cell-mediated CD8+ T cell exhaustion in hepatitis B virus-induced immunotolerance..J Immunol2014;193:1645-53

[36] Park JJ,Wahed AS,Feld JJ.Hepatitis B virus--specific and global T-cell dysfunction in chronic hepatitis B..Gastroenterology2016;150:684-95.e5 PMCID:PMC4766024

[37] Wherry EJ.T cell exhaustion..Nat Immunol2011;12:492-9

[38] Pallett LJ,Quaglia A,Jover-Cobos M.Metabolic regulation of hepatitis B immunopathology by myeloid-derived suppressor cells..Nat Med2015;21:591-600 PMCID:PMC4458139

[39] Pal S,Dey D,Shil A.Myeloid-derived suppressor cells induce regulatory T cells in chronically HBV infected patients with high levels of hepatitis B surface antigen and persist after antiviral therapy..Aliment Pharmacol Ther2019;49:1346-59

[40] Kim GA,Han S,Shim JH.High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B..Gut2018;67:945-52

[41] Maini MK,Lee CK,Reignat S.The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection..J Exp Med2000;191:1269-80 PMCID:PMC2193131

[42] Mason WS,Litwin S,Peri S.HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerant..Gastroenterology2016;151:986-98.e4

[43] Fisicaro P,Montanini B,Ferracin M.Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B..Nat Med2017;23:327-36

[44] Amadei B,Cazaly A,Zerbini A.Activation of natural killer cells during acute infection with hepatitis C virus..Gastroenterology2010;138:1536-45 PMCID:PMC4183834

[45] Axley P,Ravi S.Hepatitis C virus and hepatocellular carcinoma: a narrative review..J Clin Transl Hepatol2018;6:79-84 PMCID:PMC5863002

[46] Rosen HR.Control of HCV infection by natural killer cells and macrophages..Cold Spring Harb Perspect Med2019;a037101 PMCID:PMC7447067

[47] Gremion C,Wölk B,Reichen J.Cytotoxic T lymphocytes derived from patients with chronic hepatitis C virus infection kill bystander cells via Fas-FasL interaction..J Virol2004;78:2152-7 PMCID:PMC369426

[48] Erickson AL,Igarashi S,Houghton M.The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes..Immunity2001;15:883-95

[49] Ruhl M,Schewior K,Neumann-Haefelin C.CD8+ T-cell response promotes evolution of hepatitis C virus nonstructural proteins..Gastroenterology2011;140:2064-73

[50] Radziewicz H,Hon H,Obideen K.Impaired hepatitis C virus (HCV)-specific effector CD8+ T cells undergo massive apoptosis in the peripheral blood during acute HCV infection and in the liver during the chronic phase of infection..J Virol2008;82:9808-22 PMCID:PMC2566282

[51] Rutebemberwa A,Astemborski J,Liu L.High-programmed death-1 levels on hepatitis C virus-specific T cells during acute infection are associated with viral persistence and require preservation of cognate antigen during chronic infection..J Immunol2008;181:8215-25 PMCID:PMC2773824

[52] Owusu Sekyere S,Kraft AR,Dietz J.A heterogeneous hierarchy of co-regulatory receptors regulates exhaustion of HCV-specific CD8 T cells in patients with chronic hepatitis C..J Hepatol2015;62:31-40

[53] McMahan RH,Nishimura MI,Kemper M.Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity..J Clin Invest2010;120:4546-57 PMCID:PMC2994339

[54] Chattergoon MA,Quinn J,Buckheit RW3rd.HIV and HCV activate the inflammasome in monocytes and macrophages via endosomal Toll-like receptors without induction of type 1 interferon..PLoS Pathog2014;10:e1004082 PMCID:PMC4006909

[55] Liu Y,Zou Z,Fan Q.Hepatitis C virus entry into macrophages/monocytes mainly depends on the phagocytosis of macrophages..Dig Dis Sci2019;64:1226-37

[56] He G.NF-κB and STAT3 - key players in liver inflammation and cancer..Cell Res2011;21:159-68 PMCID:PMC3193410

[57] Shin EC,Park SH.Immune responses and immunopathology in acute and chronic viral hepatitis..Nat Rev Immunol2016;16:509-23

[58] Ren JP,Zhao J,Ning SB.Decline of miR-124 in myeloid cells promotes regulatory T-cell development in hepatitis C virus infection..Immunology2017;150:213-20 PMCID:PMC5214428

[59] Farooqi ZU,Ahmed J.Logical analysis of regulation of interleukin-12 expression pathway regulation during HCV infection..Protein Pept Lett2016;23:581-9

[60] Piconese S,Pacella I,Tripodo C.Human OX40 tunes the function of regulatory T cells in tumor and nontumor areas of hepatitis C virus-infected liver tissue..Hepatology2014;60:1494-507

[61] Della Bella S,Riva A,Benetti A.Decrease and dysfunction of dendritic cells correlate with impaired hepatitis C virus-specific CD4+ T-cell proliferation in patients with hepatitis C virus infection..Immunology2007;121:283-92 PMCID:PMC2265942

[62] Ulsenheimer A,Gruener NH,Schirren CA.Detection of functionally altered hepatitis C virus-specific CD4 T cells in acute and chronic hepatitis C..Hepatology2003;37:1189-98

[63] Cancer Genome Atlas Research Network. Electronic address: [e-mail]. Cancer Genome Atlas Research NetworkComprehensive and integrative genomic characterization of hepatocellular carcinoma..Cell2017;169:1327-41.e23 PMCID:PMC5680778

[64] Zheng C,Yoo JK,Zhang Y.Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing..Cell2017;169:1342-56.e16

[65] Kim HD,Park S,Kim MH.Association between expression level of PD1 by tumor-infiltrating CD8+ T cells and features of hepatocellular carcinoma..Gastroenterology2018;155:1936-50.e17

[66] Lim CJ,Pan L,Chua C.Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma..Gut2019;68:916-27

[67] Hoechst B,Ballmaier M,Krüger C.A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells..Gastroenterology2008;135:234-43

[68] Lin EY,Gnatovskiy L,Zhu L.Macrophages regulate the angiogenic switch in a mouse model of breast cancer..Cancer Res2006;66:11238-46

[69] Ugel S,Mandruzzato S.Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages..J Clin Invest2015;125:3365-76 PMCID:PMC4588310

[70] Li H,Guo Q,Cao X.Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1..J Immunol2009;182:240-9

[71] Zhang HH,Fei R,Wang JH.Regulatory T cells in chronic hepatitis B patients affect the immunopathogenesis of hepatocellular carcinoma by suppressing the anti-tumour immune responses..J Viral Hepat.2010;17 Suppl 1:34-43

[72] Han Y,Yang Y,Gu Y.Human CD14+ CTLA-4+ regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma..Hepatology2014;59:567-79

[73] Prieto J,Sangro B.Immunological landscape and immunotherapy of hepatocellular carcinoma..Nat Rev Gastroenterol Hepatol2015;12:681-700

[74] Chen Y,Reiberger T,Huang P.Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice..Hepatology2014;59:1435-47 PMCID:PMC3966948

[75] Sangro B,de la Mata M,Garralda E.A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C..J Hepatol2013;59:81-8

[76] El-khoueiry AB,Yau T,Kudo M.Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial..Lancet2017;389:2492-502 PMCID:PMC7539326

[77] Yau T,Finn R,Mathurin P.CheckMate 459: a randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)..Ann Oncol2019;30:v874-5

[78] Zhu AX,Edeline J,Ogasawara S.Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial..Lancet Oncol2018;19:940-52

[79] Finn RS,Merle P,Bouattour M.Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial..J Clin Oncol2020;38:193-202

[80] Yen C,Chao Y,Kang J.Preliminary results of a phase 1A/1B study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb), in patients with advanced hepatocellular carcinoma (HCC)..Ann Oncol2017;28:iii54

[81] Qin S,Meng Z,Chai X.Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial..Lancet Oncol2020;21:571-80

[82] He A,Falchook G,Gil-martin M.Cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced or metastatic hepatocellular carcinoma (HCC): Data from an expansion cohort (EC) in a phase I study..Ann Oncol2018;29:x26

[83] Wainberg ZA,Jaeger D,Marshall J.Safety and clinical activity of durvalumab monotherapy in patients with hepatocellular carcinoma (HCC)..J Clin Oncol2017;35:4071

[84] Floudas CS,Brar G,Fioravanti S.Combined immune checkpoint inhibition (ICI) with tremelimumab and durvalumab in patients with advanced hepatocellular carcinoma (HCC) or biliary tract carcinomas (BTC)..JCO2019;37:336

[85] Kelley RK,Bendell JC,Borad MJ.Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses..JCO2017;35:4073

[86] Li B,Zhu J,Fu Q.Anti-PD-1/PD-L1 blockade immunotherapy employed in treating hepatitis B virus infection-related advanced hepatocellular carcinoma: a literature review..Front Immunol2020;11:1037 PMCID:PMC7270402

[87] Pishvaian MJ,Ryoo B,Lee K.Updated safety and clinical activity results from a phase Ib study of atezolizumab 1 bevacizumab in hepatocellular carcinoma (HCC)..Ann Oncol2018;29:

[88] Finn RS,Ikeda M,Ducreux M.Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma..N Engl J Med2020;382:1894-905

[89] Ikeda M,Kudo M,Baron AD.A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC)..JCO2018;36:4076

[90] Bang Y,Lin C,Fu S.Ramucirumab (Ram) and durvalumab (Durva) treatment of metastatic non-small cell lung cancer (NSCLC), gastric/gastroesophageal junction (G/GEJ) adenocarcinoma, and hepatocellular carcinoma (HCC) following progression on systemic treatment(s)..JCO2019;37:2528

[91] Yau T,Kim T,Santoro A.Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): results from CheckMate 040..JCO2019;37:4012

[92] Kudo M,Wada Y,Sakamoto Y.First-line avelumab + axitinib in patients with advanced hepatocellular carcinoma: Results from a phase 1b trial (VEGF Liver 100)..JCO2019;37:4072

[93] Duffy AG,Makorova-Rusher O,Wedemeyer H.Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma..J Hepatol2017;66:545-51 PMCID:PMC5316490

[94] Katz SC,McCormack E,Mooring W.Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor-modified T-cell therapy for CEA+ liver metastases..Clin Cancer Res2015;21:3149-59 PMCID:PMC4506253

[95] Zhai B,Gao H,Jiang H.A phase I study of anti-GPC3 chimeric antigen receptor modified T cells (GPC3 CAR-T) in Chinese patients with refractory or relapsed GPC3+ hepatocellular carcinoma (r/r GPC3+ HCC)..JCO2017;35:3049

[96] Yu X,Liu L,Ren B.A randomized phase II study of autologous cytokine-induced killer cells in treatment of hepatocellular carcinoma..J Clin Immunol2014;34:194-203

[97] Lee JH,Lim YS,Song TJ.Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma..Gastroenterology2015;148:1383-91.e6

[98] Tan AT,Lee Krishnamoorthy T,Chua A.Use of expression profiles of HBV-DNA integrated into genomes of hepatocellular carcinoma cells to select T cells for immunotherapy..Gastroenterology2019;156:1862-76.e9

[99] Wisskirchen K,Schreiber S,Weigand L.Isolation and functional characterization of hepatitis B virus-specific T-cell receptors as new tools for experimental and clinical use..PLoS One2017;12:e0182936 PMCID:PMC5549754

[100] Gehring AJ,Ho ZZ,Ruedl C.Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines..J Hepatol2011;55:103-10

[101] Qasim W,Gehring AJ,Schurich A.Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient..J Hepatol2015;62:486-91

[102] Sahin U.Personalized vaccines for cancer immunotherapy..Science2018;359:1355-60

[103] Buonaguro L.Developments in cancer vaccines for hepatocellular carcinoma..Cancer Immunol Immunother2016;65:93-9

[104] Nakagawa H,Kobayashi E,Hamana H.Association between high-avidity T-cell receptors, induced by alpha-fetoprotein-derived peptides, and anti-tumor effects in patients with hepatocellular carcinoma..Gastroenterology2017;152:1395-406.e10

[105] Sawada Y,Nobuoka D,Kuronuma T.Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival..Clin Cancer Res2012;18:3686-96

[106] Sawada Y,Shimomura M,Endo I.Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes..Int J Oncol2015;46:28-36 PMCID:PMC4238729

[107] Greten TF,Korangy F,Barget N.A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma..BMC Cancer2010;10:209 PMCID:PMC2882353

[108] Harrington K,Kelly B,Soria JC.Optimizing oncolytic virotherapy in cancer treatment..Nat Rev Drug Discov2019;18:689-706

[109] Heo J,Ruo L,Rose S.Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer..Nat Med2013;19:329-36 PMCID:PMC4268543

[110] Park B,Liu T,Kim J.Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial..Lancet Oncology2008;9:533-42

[111] Moehler M,Lee HC,Chao Y.Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)..Oncoimmunology2019;8:1615817 PMCID:PMC6682346

[112] Ma C,Heinrich B,Zhang Q.Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells..Science2018;360:eaan5931 PMCID:PMC6407885